Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002005051 | SCV002248256 | uncertain significance | Cohen syndrome | 2022-05-25 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 933 of the VPS13B protein (p.Gln933Glu). This variant is present in population databases (rs773412105, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004970681 | SCV005531722 | uncertain significance | Inborn genetic diseases | 2024-10-06 | criteria provided, single submitter | clinical testing | The c.2797C>G (p.Q933E) alteration is located in exon 19 (coding exon 18) of the VPS13B gene. This alteration results from a C to G substitution at nucleotide position 2797, causing the glutamine (Q) at amino acid position 933 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |